Suven Life Sciences Ltd
Suven Life Sciences Q4 FY26 investor presentation: Revenue & Margins
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Suven Life Sciences Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentationreports, not management guidance.
The short version
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. The provided document (3303.pdf) does not contain any information on EBITDA, operating margin, profit (PAT) figures for the quarter, year-on-year changes, or any explicit margin outlook.
From Suven Life Sciences Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
Profitability & Margins
See what Suven Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
2 more points from Suven Life Sciences Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Suven Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The presentation does not report any details about order book, order inflow, or pending orders.
- It primarily focuses on clinical developments and presentations related to Suven Life Sciences' drug candidates, especially Samelisant (SUVN-G3031).
- No financial or commercial order-related metrics such as order book or order inflow are mentioned in the document.
- The content emphasizes clinical study statuses, poster presentations at SLEEP-2026, and company pipeline details.
Suven Life Sciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2 Cr, net loss ₹46 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suven Life Scie.'s management said in earlier quarters
Others in Healthcare Services this season
- Invicta Diagnos. (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnos.'s Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
- Gaudium IVF (Q4 FY26)
Revenue growth seen in FY26: INR 104.35 crore, a 47.56% increase from FY25. Key concall takeaways from Gaudium IVF's Q4 FY26 earnings call — and how it ranks…
Arthneeti Pro · Annual
Suven Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Suven Life Sciences Ltd Q4 FY26 results?
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. The provided document (3303.pdf) does not contain any information on EBITDA, operating margin, profit (PAT) figures for the quarter, year-on-year changes, or any explicit margin outlook.
What is Suven Life Sciences Ltd share price analysis?
Suven Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹8,577 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suven Life Sciences Ltd planning capital expenditure?
The provided presentation pages do not describe any capex, capacity expansion, new plant, or project investments with amounts, status, or timelines.
Keep Suven Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.